MedPage Today) — Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed.
In patients with mostly undifferentiated pleomorphic sarcomas, 2…
MedPage Today) — Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed.
In patients with mostly undifferentiated pleomorphic sarcomas, 2…
